NCT05015972

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

A Study of CTA30X UCAR-T Cell Injection in the Treatment of Patients With r/r CD19+ B Hematologic Malignancies

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Academic / Other
• Sex: All
• Age: 3 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm, open-label, single-center prospective study to determinethe safety and efficacy of CTA30X UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B Hematologic Malignancies

Detailed description

The main aim of the study is to determine the safety and efficacy of CTA30X UCAR-T in R/R B Hematologic Malignancies. CTA30X UCAR-T is an allogeneic chimeric antigenreceptor T-cell (CAR-T) therapy that targets CD19 and B-cell Hematologic Malignancies. The study will include 72 subjects to receive CTA30X UCAR-T singleinfusion.

Conditions

• B-cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	CTA30X UCAR-T injection	CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.

Timeline

• Start date: 2021-08-20
• Primary completion: 2023-06-30
• Completion: 2023-12-31
• First posted: 2021-08-23
• Last updated: 2022-11-29

Locations

1 site across 1 country: China